How to Get Vyvanse in Pennsylvania

What Vyvanse Is and Why Pennsylvania Has Specific Rules

Vyvanse is an FDA-approved prodrug of d-amphetamine indicated for ADHD in patients 6 years and older and for moderate-to-severe binge-eating disorder (BED) in adults. The FDA approved lisdexamfetamine for ADHD in 2007 and for BED in 2015. Because it is a Schedule II controlled substance under the federal Controlled Substances Act, Pennsylvania layers additional requirements on top of federal law.

Pennsylvania Schedule II Basics

Pennsylvania enforces the federal Schedule II rule: no refills. Every calendar month, a patient must present a new prescription, either on paper or via Pennsylvania's Prescription Drug Monitoring Program (PDMP)-connected electronic prescribing system. Prescribers must query the Pennsylvania PDMP (operated through the Pennsylvania Department of Health) before issuing any Schedule II prescription. Pennsylvania Act 191 of 2014 codified mandatory PDMP checks for controlled substances.

Why the Drug Class Matters for Access

Stimulant shortages since 2022 have affected Pennsylvania the same way they have affected other states. Patients should verify stock at their chosen pharmacy before the prescriber sends the electronic prescription, because a Schedule II prescription cannot be transferred between pharmacies once partially filled under DEA regulations. The DEA's 21 CFR 1306.13 governs Schedule II partial fills.

Step 1: Find a Qualified Prescriber in Pennsylvania

Who Can Legally Prescribe Vyvanse in Pennsylvania

Three clinician types may prescribe Vyvanse in Pennsylvania, provided each holds an active DEA Schedule II registration:

• MDs and DOs with a Pennsylvania medical license
• Certified Registered Nurse Practitioners (CRNPs) operating under a collaborative agreement or, since Act 136 of 2022, independently after 3 years and 3,000 hours of clinical experience
• Physician Assistants (PA-Cs) with a supervising physician and a Schedule II prescribing agreement on file with the Pennsylvania State Board of Medicine

Psychiatrists and neurologists see the highest volume of ADHD patients in the state, but many adult primary-care physicians also prescribe lisdexamfetamine. Pediatric patients (ages 6 to 17) are most often managed by child psychiatrists or developmental pediatricians.

What the Initial Evaluation Covers

A complete ADHD evaluation typically includes a structured clinical interview using DSM-5 criteria, validated rating scales (Adult ADHD Self-Report Scale for adults, Conners for children), a review of prior records, and a cardiovascular screen. The American Academy of Pediatrics 2019 clinical practice guideline recommends evidence-based ADHD rating scales for diagnosis and monitoring.

Expect the initial appointment to run 45 to 90 minutes. A follow-up to assess response is typically scheduled at four weeks.

Step 2: Telehealth Prescribing in Pennsylvania

Current Federal Telehealth Rules and Pennsylvania

The federal DEA's telemedicine flexibilities, first introduced during the COVID-19 public health emergency, have been extended through December 31, 2025. Under these rules, a DEA-registered prescriber may prescribe Schedule II controlled substances, including Vyvanse, via audio-video telehealth without a prior in-person visit, as long as the prescriber is licensed in the state where the patient is located at the time of the visit. The DEA published its most recent extension of telemedicine prescribing rules in the Federal Register in 2024.

Pennsylvania law does not impose additional restrictions beyond federal requirements for telehealth controlled-substance prescribing, making it one of the more accessible states for remote ADHD care. Patients must be physically located in Pennsylvania at the time of the telehealth visit for a Pennsylvania-licensed prescriber to issue the prescription.

How to Prepare for a Telehealth ADHD Visit

Before the appointment, gather the following:

• Prior ADHD evaluations, neuropsychological reports, or school records documenting symptoms
• A list of current medications, including supplements
• A reliable internet connection and camera (audio-only is generally insufficient for a first controlled-substance evaluation)
• Photo ID and insurance card

Most telehealth platforms will send a secure intake form covering symptom history, family psychiatric history, sleep patterns, and cardiovascular risk. Complete it at least 24 hours before the visit.

Telehealth and the Pennsylvania PDMP

Telehealth prescribers operating in Pennsylvania must still query the Pennsylvania PDMP before issuing a Vyvanse prescription, the same as in-person providers. Failure to do so violates Act 191 and exposes the prescriber to license sanctions. Patients should expect a short delay at the end of the visit while the prescriber completes this check. Details on prescriber PDMP obligations are at the Pennsylvania Department of Health PDMP portal.

Step 3: The Prescription and Documentation Process

What the Prescription Must Contain

Under 21 CFR 1306.05, a valid Schedule II prescription for Vyvanse must include the patient's full name and address, the prescriber's DEA registration number, the drug name and strength, quantity written out in words and numerals, directions for use, and the date of issuance. Electronic prescriptions for controlled substances (EPCS) must use a DEA-compliant two-factor authentication system.

Pennsylvania permits prescribers to issue up to a 90-day supply of a Schedule II controlled substance on a single prescription form, using multiple sequential "do not fill before" dates. Pennsylvania Department of Health guidance on 90-day Schedule II supplies is available through the state PDMP resources.

What Documentation Prior Authorization Requires

Most Pennsylvania commercial insurers and Medicaid managed-care organizations (MCOs) require prior authorization (PA) for Vyvanse, particularly as a brand-name product when generic lisdexamfetamine is available. Expect the PA packet to include:

• DSM-5 diagnosis code (F90.0, F90.1, or F90.2 for ADHD subtypes; F50.81 for BED)
• Documentation of symptom severity using a validated scale
• Trial and failure of at least one generic stimulant (usually methylphenidate or amphetamine salts) within the prior 12 months, unless medically contraindicated
• Labs: fasting metabolic panel and, for patients over 40 or with cardiac risk factors, a 12-lead ECG

Pennsylvania Medicaid (Medical Assistance) covers Vyvanse for both ADHD and BED indications with prior authorization per the PA Drug Formulary.

Step 4: Labs and Screening Before Starting Vyvanse

Required and Recommended Lab Work

No single universal lab panel is mandated before initiating lisdexamfetamine, but Pennsylvania prescribers following American Academy of Child and Adolescent Psychiatry (AACAP) and American Academy of Pediatrics (AAP) guidance routinely obtain:

| Test | Rationale | |---|---| | Blood pressure and heart rate | Stimulants raise both; baseline needed | | Weight and BMI | Appetite suppression monitoring | | Complete metabolic panel | Hepatic and renal function | | TSH | Rule out hyperthyroidism mimicking ADHD | | 12-lead ECG | Cardiac screening in patients with risk factors or family history of arrhythmia | | Urine drug screen | Rule out concurrent stimulant or other substance use |

The American Heart Association's 2008 scientific statement recommends ECG before stimulant initiation in pediatric patients with cardiac risk factors.

Cardiovascular Risk Assessment

Vyvanse carries an FDA black-box warning for abuse potential and a contraindication in patients with symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, glaucoma, or agitated states. The Vyvanse prescribing information on FDA AccessData details all contraindications. Patients with a personal or first-degree family history of sudden cardiac death, Wolff-Parkinson-White syndrome, or prolonged QT should have cardiology clearance before starting any amphetamine product.

Step 5: What the Clinical Evidence Says About Vyvanse

ADHD Efficacy Data

Wigal et al. (2017, Journal of Attention Disorders, N=348 adults) found that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV total scores compared to placebo (P<0.001), with effect sizes consistent with earlier key trials. Wigal et al. 2017, PubMed PMID 26861148. The drug's prodrug design, requiring enzymatic cleavage by red blood cell hydrolases to release active d-amphetamine, produces a smoother pharmacokinetic profile than immediate-release amphetamine salts and an onset of 1.5 to 2 hours with duration up to 14 hours. Pharmacokinetic details are documented in the FDA label.

Binge-Eating Disorder Data

The key BED trials (Study 1 and Study 2, each 11 to 12 weeks, total N=773) showed lisdexamfetamine 50 mg and 70 mg produced significantly more binge-free days than placebo. The FDA Medical Review for lisdexamfetamine BED is available via AccessData. A 2016 Cochrane review of pharmacotherapy for BED concluded stimulant medications produced short-term reductions in binge frequency, though long-term data remain limited. Brownley et al. Cochrane Database Syst Rev 2016.

Dosing Framework

Standard Pennsylvania clinical practice follows the FDA-approved titration schedule. Starting dose is 30 mg orally each morning. Dose increases of 10 mg to 20 mg per week are permitted to a maximum of 70 mg/day. Most adults stabilize between 50 mg and 70 mg. Pediatric patients (ages 6 to 17) follow an identical titration range of 30 mg to 70 mg. The capsule may be opened and dissolved in water for patients who cannot swallow capsules whole, but it must never be crushed and snorted, given its Schedule II abuse classification. FDA label administration instructions.

Step 6: Pennsylvania Pharmacies and Dispensing Rules

Choosing a Pharmacy

Pennsylvania has no state restriction limiting which licensed pharmacies may dispense Schedule II medications, provided the pharmacy holds a current DEA registration. Major chains (CVS, Walgreens, Rite Aid, Giant, Walmart) and independent pharmacies all dispense lisdexamfetamine. Due to nationwide stimulant shortages, patients should call ahead to confirm stock before having the prescription sent electronically. The FDA has tracked ongoing amphetamine product shortages since 2022.

Mail-Order and Specialty Pharmacy Options

Mail-order pharmacies registered with the DEA and licensed in Pennsylvania may dispense Schedule II controlled substances to Pennsylvania residents. The prescription must be transmitted electronically via EPCS or mailed as an original paper prescription. DEA 21 CFR 1306.21 governs mail-order dispensing of Schedule II substances.

503A Compounding Pharmacies in Pennsylvania

Pennsylvania-licensed 503A compounding pharmacies may compound lisdexamfetamine preparations for individual patients, provided a valid prescription exists and the preparation is not a copy of a commercially available product without a clinical justification. This is relevant primarily for patients requiring a dose form not commercially available (for example, a liquid suspension for a pediatric patient unable to use capsules). FDA guidance on 503A compounding pharmacies. Compounded lisdexamfetamine is not a less expensive alternative to brand-name Vyvanse; generic lisdexamfetamine dimesylate (Zogenix, Aurobindo, and others) serves that function and costs substantially less. Generic lisdexamfetamine is listed in the FDA Orange Book.

Prescription Transfer Rules in Pennsylvania

A Schedule II prescription may not be transferred between pharmacies in Pennsylvania after it has been partially or fully filled. This is a federal DEA prohibition, not a Pennsylvania-specific rule, and applies nationwide. Patients moving to Pennsylvania from another state should request a new prescription from a Pennsylvania-licensed prescriber rather than attempting to transfer an out-of-state Schedule II prescription. The new prescriber will review out-of-state PDMP records if the prescriber has interstate access, or will request records from the prior state. Interstate PDMP data sharing is described in the PDMP Training and Technical Assistance Center resources.

Step 7: Insurance Coverage and Cost in Pennsylvania

Pennsylvania Medicaid (Medical Assistance)

Pennsylvania Medicaid covers Vyvanse for ADHD and BED with prior authorization. Generic lisdexamfetamine is typically on the preferred tier without prior authorization. Managed-care organizations (Highmark Wholecare, UPMC for Life, AmeriHealth Caritas, Geisinger Health Plan) each maintain their own formulary tiers, so patients should confirm coverage with their specific MCO. Pennsylvania's Preferred Drug List is maintained by the Department of Human Services.

Commercial Insurance

Most commercial plans in Pennsylvania (Highmark, Independence Blue Cross, Aetna, Cigna) place brand-name Vyvanse on Tier 3 or Tier 4. Without prior authorization approval, the out-of-pocket cost for 30 capsules of Vyvanse 50 mg can exceed $350. Generic lisdexamfetamine 50 mg/30 capsules typically retails for $80 to $120 without insurance and below $30 with GoodRx or similar discount programs at major Pennsylvania chains. GoodRx pricing is not a primary medical source but FDA label cost data appears in FDA drug approval summaries.

Takeda Patient Assistance

Takeda offers a co-pay savings card for commercially insured patients that may reduce out-of-pocket costs to as low as $30 per month. Uninsured or underinsured patients may qualify for Takeda's patient assistance program. Takeda product assistance is listed on the FDA Vyvanse label supplemental pages.

Monitoring After Starting Vyvanse in Pennsylvania

Follow-Up Schedule

The AAP 2019 guideline recommends assessment of ADHD symptom response and side effects within 30 days of starting or adjusting stimulant therapy, then every three to six months once a stable dose is reached. AAP 2019 ADHD clinical practice guideline. In practice, Pennsylvania prescribers typically see patients monthly for the first three months to issue Schedule II prescriptions and monitor response.

What Prescribers Track

At each visit or telehealth check-in, the clinician records:

• Blood pressure and heart rate (stimulants raise systolic BP by 2 to 4 mmHg on average)
• Weight (appetite suppression may cause clinically meaningful weight loss, particularly in children)
• Sleep quality (Vyvanse's 14-hour duration can delay sleep onset if taken after 9 a.m.)
• ADHD rating scale scores to document ongoing response
• Presence of new cardiovascular symptoms, tics, or psychiatric symptoms

The AACAP Practice Parameter for ADHD recommends ongoing monitoring of growth, cardiovascular parameters, and psychiatric comorbidities.

When to Re-Evaluate the Diagnosis

A patient who does not respond to Vyvanse 70 mg after four to six weeks of treatment warrants re-evaluation. Possibilities include misdiagnosis, sleep disorder, substance use, thyroid dysfunction, or a comorbid mood disorder dominating the clinical picture. The NIMH notes that ADHD commonly co-occurs with anxiety, depression, and learning disabilities.